The present invention relates to apparatus and methods for providing embolic protection in a patient's vascular system. In particular, it relates to catheters intended for transcatheter heart valve delivery and other intravascular interventional procedures which incorporate an embolic filter.
Cerebral embolism is a known complication of cardiac surgery, cardiopulmonary bypass and catheter-based interventional cardiology and electrophysiology procedures. Embolic particles, which may include thrombus, atheroma and lipids, may become dislodged by surgical or catheter manipulations and enter the bloodstream, embolizing in the brain or other vital organs downstream. Cerebral embolism can lead to neuropsychological deficits, stroke and even death. Other organs downstream can also be damaged by embolism, resulting in diminished function or organ failure.
Prevention of embolism would benefit patients and improve the outcome of these procedures. Given that potential emboli are often dislodged during catheter-based procedures, it would be advantageous to deploy an embolic protection system as part of a catheter-based vascular procedure, such as transcatheter aortic valve replacement (TAVR). Further, the use of transcranial doppler (TCD) during TAVR has shown that cerebral emboli are generated primarily during the procedural steps of crossing the native valve and deploying the TAVR valve (Reference Kahlert, et al, Circulation, 2012). Therefore, the integration of an embolic protection device on the TAVR delivery system itself would have the advantage that the protection is in place for the most critical steps of the procedure. Another advantage would come by integrating the embolic protection system on the catheter itself that is being used to perform the procedure, such as a transcatheter valve delivery system or electrophysiology catheter. Other embolic protection systems require separate procedural steps for installing the protector prior to the interventional or diagnostic procedure and removing it after the procedure. In many cases a different access site is required as well. The present invention avoids both the extra step and the need for an extra access site. Yet another advantage would come from providing an integrated embolic protection device that does not increase the overall diameter of the catheter.
Devices for preventing embolisms and similar events are described in the following patents and patent applications, which are hereby incorporated by reference: U.S. Pat. Nos. 10,166,094; 9,877,821; 9,744,023; 9,144,485; 8,968,354; 8,740,930; 8,420,902; 8,383,788; 8,337,519; 8,123,779; 8,052,717; 7,537,600; 7,044,958; 6,537,297; 6,499,487; 6,371,935; 6,361,545; 6,254,563; 6,139,517; 5,769,816; U.S. Pat. App. 2019/0015152; U.S. Pat. App. 2018/0206970; U.S. Pat. App. 2018/0042390; U.S. Pat. App. 2016/0317277; U.S. Pat. App. 2015/0366650; U.S. Pat. App. 2014/0214069; U.S. Pat. App. 2013/267993; U.S. Pat. App. 2012/271340; U.S. Pat. App. 2010/0312268; U.S. Pat. App. 2010/0010535; U.S. Pat. App. 2004/0215167; U.S. Pat. App. 2003/0100940; and PCT App. WO2004/019817.
A prosthetic heart valve delivery catheter having integrated embolic protection according to the principles of the present invention inhibits the release of emboli into the aorta, the aortic arch or branch vessels, and other vasculature to protect the brain and other downstream organs from embolization during transvascular prosthetic heart valve replacement procedures. Unlike most other embolic protection solutions, the embolic filter is integrated into an interventional or diagnostic catheter, such as a transcatheter heart valve delivery system.
In a first aspect, the present invention provides a prosthetic heart valve delivery catheter system having integrated embolic protection. The catheter system typically comprises a catheter shaft having a distal portion, a prosthetic valve disposed on the distal portion of the catheter shaft; and an embolic filter disposed on the distal portion of the shaft at a location proximal of the prosthetic valve. The embolic filter has a collapsed configuration and a deployed configuration, and an outer periphery of the filter is configured to contact a blood vessel wall in the expanded configuration. In some embodiments, the embolic filter comprises a filter structure having a narrow end coupled to the shaft and an open end located distally of the narrow end.
In specific embodiments, the narrow end of the filter structure may fixedly attached to the catheter shaft. In alternative embodiments, the narrow end of the filter structure is slidably mounted on the catheter shaft. The catheter may further comprise at least one of a proximal stop on the catheter shaft for limiting proximal movement of the embolic filter on the distal portion of the catheter shaft and a distal stop on the catheter shaft for limiting distal movement of the embolic filter on the distal portion of the catheter shaft.
In further specific embodiments, the filter may comprise a filter membrane and a support structure. The support structure may comprise a plurality of self-expanding axial struts connected at their proximal ends to the catheter shaft so as to open a distal end of the filter member to form a cone when released from constraint. The axial struts may have atraumatic distal tips.
In other embodiments, the filter may comprise a self-expanding conical filter. For example, the embolic filter comprises a porous material comprising a fabric of knitted, woven, or nonwoven fibers, filaments, or wires. The porous material may be made of a resilient metal, polymer material, a malleable material, a plastically deformable material, a shape-memory material, or combinations thereof. The porous material will typically have a pore size chosen to prevent emboli over a predetermined size from passing through.
In a second aspect, the present invention provides systems comprising a catheter as described above in combination with an outer delivery sheath configured to maintain the embolic filter in a collapsed configuration.
In a third aspect, the present invention provides a prosthetic heart valve delivery catheter having integrated embolic protection. The prosthetic heart valve delivery catheter typically comprises a catheter shaft having a distal portion, a prosthetic valve disposed on the distal portion of the catheter shaft; and an embolic filter disposed on the distal portion of the shaft at a location proximal of the prosthetic valve. The embolic filter will usually have a collapsed configuration and a deployed configuration and, in the expanded configuration, an outer periphery of the filter contacts a blood vessel wall The embolic filter will typically comprise a filter membrane and a support structure, wherein the support structure comprises a cage having a distal collar and a proximal collar attached to the distal portion of the catheter shaft.
In specific embodiments, at least one of the distal collar and the proximal collar is slidably attached to the distal portion of the catheter shaft. In other embodiments, at least one of the distal collar and the proximal collar is fixedly attached to the distal portion of the catheter shaft. For example, at least one of the distal collar and the proximal collar is fixedly attached to the distal portion of the catheter shaft. In other examples, at least one of the distal collar and the proximal collar is configured to be axially translated to expand and contract the cage. Typically, the cage is self-expanding so that it can be radially constrained for delivery and released from radial constraint for deployment. In still further examples, the cage has a conically tapered distal end, a conically tapered proximal end, and a cylindrical wall portion therebetween, wherein the filter membrane covers at least the conically tapered proximal end and does not cover the conically tapered distal end.
In a fourth aspect, the present invention provides a prosthetic heart valve delivery catheter having integrated embolic protection. The catheter comprises a catheter shaft having a distal portion, a prosthetic valve disposed on the distal portion of the catheter shaft, and an embolic filter disposed on the distal portion of the shaft at a location proximal of the prosthetic valve. The embolic filter typically has a collapsed configuration and a deployed configuration where an outer periphery of the filter is configured to contact a blood vessel wall. The embolic filter usually further comprises a cylindrical wall portion located proximal of the prosthetic valve and configured to cover a patient's aortic branch vessels and a conical wall portion proximal of the cylindrical wall portion.
In specific embodiments, a cylindrical wall portion and a conical wall portion are not continuous. For example, at least one of cylindrical wall portion and the conical wall portion may be fixedly attached to the distal portion of the catheter shaft. In other examples, at least one of cylindrical wall portion and the conical wall portion is slidably attached to the distal portion of the catheter shaft. In still other examples, at least one of cylindrical wall portion and the conical wall portion is self-expanding. In any of these examples, at least one of cylindrical wall portion and the conical wall portion is balloon expandable.
In a fifth aspect, the present invention provides a prosthetic heart valve delivery catheter having integrated embolic protection, where catheter comprises a catheter shaft having a distal portion, a prosthetic valve disposed on the distal portion of the catheter shaft, and an embolic filter disposed on the distal portion of the shaft at a location proximal of the prosthetic valve. The embolic filter typically has a collapsed configuration and a deployed configuration where an outer periphery of the filter is configured to contact a blood vessel wall. The embolic filter will usually further comprise a cylindrical wall having an open distal end and a closed proximal end sealing coupled to the catheter shaft, where a proximal region of the cylindrical wall is movably everted and allows the open distal end to axially translate relative to the catheter shaft while the closed proximal end remains stationary relative to the catheter shaft.
In specific embodiments, the closed proximal end is fixed to the catheter shaft. For example,
the closed proximal end may slidably couple to the catheter shaft. At least the distal portion of the cylindrical wall may be self-expanding and at least at the distal portion of the cylindrical wall may comprise a self-expanding filter.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
For purposes of this patent application, the term “distal” refers to the end of the device that is farthest away from the operator, and closest to the heart. This is also the “upstream” direction of blood flow. The term “proximal” refers to the end of the device nearer to the operator, toward the direction of the access site where the device has been introduced into the body, and farthest away from the heart. This is also the “downstream” direction of blood flow.
The self-expanding, conical embolic filter 12 typically comprises a mesh or other filter material having a mesh size suitable for embolic capture and a self-expanding support structure, such as a plurality of radially self-expanding struts 22 to ensure full expansion of the mesh or other filter material. As illustrated, the radially self-expanding struts 22 have atraumatic distal tips to contact the aortic wall, e.g. distal ends of the struts may be curved, coiled, have protective pads, or have other structures to inhibit tissue injury.
The self-expanding, conical embolic filter 12 is typically deployed by retracting a constraining sheath 26 (compare
After positioning the first constraining sheath 226 and prosthetic valve 220 in the aortic valve V, the filter 212 is deployed by retraction of the second sheath 228, allowing the filter to expand (
The embolic filter may be a mesh or other filter structure made of knitted, woven or nonwoven fibers, filaments or wires that will have a pore size chosen to allow blood to pass through but prevent emboli above a certain size from passing through. The embolic filter may also consist of a non-woven sheet, such as a thin sheet of polymer or metal, that has been perforated with holes of a single size or different sizes. The embolic filter material may be made of a metal, a polymer or a combination thereof and may optionally have an antithrombogenic coating on its surface. The embolic filter may also consist of some combination of a perforated sheet and a fiber-based mesh or other filter material or other filter structure. The embolic filter may consist of a single layer or multiple layers of any of the above configurations to increase the filtering efficiency and reduce the effective pore size.
The embolic protection device is delivered in an undeployed or retracted condition. A tubular outer delivery sheath may be used to maintain the embolic protection device in the undeployed condition. (
Alternatively, the filter may be deployed via the inflation of balloon inside the filter, which may be cylindrically or conically shaped, or otherwise shaped to match the geometry of the filter. Such a filter may be retrieved by withdrawing it into a retrieval sheath (
Another alternative delivery mechanism is to reduce the effective length of the embolic filter with a member attached to either the distal or proximal end (or both). In an embolic filter with a design such as shown in
The catheter may be configured as a diagnostic catheter, a guiding catheter or therapeutic catheter. A specific example would be the delivery system for a transcatheter aortic valve.
The embolic filter will typically have at least one open end and define one or more internal collection regions which receive and capture emboli entering with blood flow through the open end. In other configurations, the embolic filter may have two open ends, for example having a cylindrical configuration which allows blood to flow in one end and out from the other end.
In many embodiments, the filter membranes will be self-supporting in the deployed condition. By self-supporting it is meant that the filter membrane can be deployed without further support into a three-dimensional configuration that maintains sufficient contact with the vessel wall to form an adequate seal to prevent emboli above a certain size from passing around the outside of the embolic protection device. In one example, the embolic filter can be constructed of a resilient mesh or other filter material that can be compressed into the undeployed condition and will self-expand into the deployed condition. Such structures are described in U.S. Pat. No. 9,877,821, previously incorporated herein by reference.
In another example, the embolic filter may comprise a filter membrane, matrix, or the like and a separate supporting structure. The filter membrane may comprise any known structure for filtering emboli from blood, including meshes, perforated sheets, porous sheets, fibrous structures, and the like, or any combinations thereof. The filter membrane can be resilient, slack, plastically deformable, or combinations thereof.
The supporting structure may be located externally to the filter membrane, internally within the filter membrane, or both eternally and internally. For example, the supporting structure may comprise a framework that includes one or more longitudinal struts or hoops that are attached to or otherwise engage the filter membrane to hold the filter membrane in its opened or deployed configuration with the aorta or other target blood vessel. The hoops and/or struts may be formed of a resilient metal, polymer, or other material to provide a self-expanding framework that assumes a low profile or narrow configuration when constrained by a sheath for delivery and which assumes an expanded or deployed configuration when released from constraint. Alternatively, the framework or other support structure may comprise a malleable or plastically deformable material to provide expansion by applying a radial outward force to an interior of the support structure, typically using an inflatable balloon or other expansion mechanism.
Hybrid constructions that combine features of the self-supporting structure and the frame-supported structure may also be used. Hybrid deployment methods, such as balloon-assisted self-expansion or longitudinal compression of the support structure can also be utilized.
The support structures and the filter membranes of the embolic filters will often have the same lengths, but embolic filter may also be constructed with the embolic filter membrane being longer or shorter than the supporting structure. Specific relative longitudinal dimensions of the filter membranes of the embolic filters may be as shown in the drawings. In another alternate construction, the support structure and/or filter membrane can be conical with and enlarged or base end of the cone being positioned on the upstream side.
The embolic filter can be retracted and withdrawn with the catheter after the diagnostic or interventional procedure has been completed. Optionally, the embolic filter may include features to assist in retracting the device for retrieval from the patient's aorta. For example, a conical guiding structure may be slidably attached to the catheter at the proximal end of the device, the purpose of which is to assist the embolic filter in collapsing when a retrieval sheath is advanced along the conical guiding structure. In another example, portions of the embolic filter may be constructed with retraction members that are configured like purse strings or lassos around the circumference of the device. A pull loop or other graspable structure near the downstream end of the embolic filter is connected to the retraction members by one or more connecting members. In one preferred embodiment, the embolic filter is configured to close its upstream end first to assure that any captured emboli do not migrate out of the filter during retrieval. This can be accomplished by providing one or more pull loops for selectively retracting different sections of the device. The retraction members and connecting members may be made of suture, wire, plastic filament or a combination of these materials. In an alternate construction, the “Stent” Support Structure described above may also be configured to serve as the retraction members.
The embolic filter may be fixedly attached to the catheter or attached via a slidable attachment, or some combination of the two. A sliding attachment can consist of one or more rings, roller bearings or other structures that allow the embolic protection device to slide freely on the catheter. The sliding attachment will preferably have a low coefficient of friction and/or a lubricious coating so that movement of a catheter through the sliding attachment will not jostle or dislodge the embolic protection device. Alternatively, the sliding attachment can contain an additional sealing element, such as resilient flaps, an iris structure, or an expandable sealing material.
The overall undeployed diameter of the embolic filter as collapsed for delivery (including the diameter of its constraining sheath) preferably will be no larger than the largest section of the catheter (such as the collapsed diameter of a prosthetic valve, including its constraining sheath), which is most likely in the distal section of the catheter. In the case of a valve delivery system, the catheter is typically reduced in size proximal to the valve, which would potentially allow the integration of an embolic filter and its constraining member without changing the overall tracking profile of the valve delivery system.
The embolic filter is in an undeployed condition on the catheter as it is inserted into a patient's aorta. The embolic filter is ideally deployed in the ascending aorta prior to the ostia of the cerebral arteries. Optionally, a delivery sheath may be used to hold the embolic filter in the undeployed position. The embolic filter can also be constrained for delivery by crimping it onto a balloon catheter, or by elongating its support structure to reduce its diameter.
The entire embolic filter or a portion of it may be coated with an anti-thrombogenic coating, for example a bonded heparin coating, to reduce the formation of clots that could become potential emboli. Alternatively, or in addition, the embolic filter or a portion of it may have a drug-eluting coating containing an anti-inflammatory or anti-stenosis agent. The embolic filter of the present invention can also be used for embolic protection of other organ systems. For example, an embolic filter can be deployed in the patient's descending aorta for preventing embolic particles in the aortic blood flow from entering the renal arteries and embolizing in the patient's kidneys.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application claims the benefit of prior provisional patent application Ser. No. 62/844,941, filed on May 8, 2019, and Ser. No. 62/804,909, filed on Feb. 13, 2019, the full disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4723549 | Wholey et al. | Feb 1988 | A |
4790809 | Kuntz | Dec 1988 | A |
5108419 | Reger et al. | Apr 1992 | A |
5197485 | Grooters | Mar 1993 | A |
5769816 | Barbut et al. | Jun 1998 | A |
5769819 | Schwab et al. | Jun 1998 | A |
5797880 | Erskine | Aug 1998 | A |
5800525 | Bachinski et al. | Sep 1998 | A |
5807327 | Green et al. | Sep 1998 | A |
6013051 | Nelson | Jan 2000 | A |
6083239 | Addis | Jul 2000 | A |
6117154 | Barbut et al. | Sep 2000 | A |
6120534 | Ruiz | Sep 2000 | A |
6139517 | Macoviak et al. | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6245012 | Kleshinski | Jun 2001 | B1 |
6254563 | Macoviak et al. | Jul 2001 | B1 |
6254633 | Pinchuk et al. | Jul 2001 | B1 |
6258120 | McKenzie et al. | Jul 2001 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6355051 | Sisskind et al. | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6371935 | Macoviak et al. | Apr 2002 | B1 |
6461370 | Gray et al. | Oct 2002 | B1 |
6499487 | McKenzie et al. | Dec 2002 | B1 |
6511496 | Huter et al. | Jan 2003 | B1 |
6537297 | Tsugita et al. | Mar 2003 | B2 |
6547760 | Samson et al. | Apr 2003 | B1 |
6682543 | Barbut et al. | Jan 2004 | B2 |
6692513 | Streeter et al. | Feb 2004 | B2 |
6695864 | Macoviak et al. | Feb 2004 | B2 |
6709415 | Navia et al. | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6746469 | Mouw | Jun 2004 | B2 |
6808520 | Fourkas et al. | Oct 2004 | B1 |
7044958 | Douk et al. | May 2006 | B2 |
7229463 | Sutton et al. | Jun 2007 | B2 |
7232453 | Shimon | Jun 2007 | B2 |
7235060 | Kraus | Jun 2007 | B2 |
7537600 | Eskuri | May 2009 | B2 |
7758606 | Streeter et al. | Jul 2010 | B2 |
7766932 | Melzer et al. | Aug 2010 | B2 |
8052717 | Mujkanovic | Nov 2011 | B2 |
8114114 | Belson | Feb 2012 | B2 |
8123779 | Demond et al. | Feb 2012 | B2 |
8298258 | Anderson et al. | Oct 2012 | B2 |
8308754 | Belson | Nov 2012 | B2 |
8337519 | Wasicek | Dec 2012 | B2 |
8382788 | Galdonik et al. | Feb 2013 | B2 |
8383788 | Oliviero | Feb 2013 | B2 |
8414482 | Belson | Apr 2013 | B2 |
8420902 | Gilsinger | Apr 2013 | B2 |
8430904 | Belson | Apr 2013 | B2 |
8679149 | Belson | Mar 2014 | B2 |
8728114 | Belson | May 2014 | B2 |
8740930 | Goodwin | Jun 2014 | B2 |
8968354 | Wang et al. | Mar 2015 | B2 |
9107734 | Belson | Aug 2015 | B2 |
9144485 | Bergheim | Sep 2015 | B2 |
9492265 | Russell et al. | Nov 2016 | B2 |
9744023 | Wang et al. | Aug 2017 | B2 |
9827085 | Russell et al. | Nov 2017 | B2 |
9877821 | Russell et al. | Jan 2018 | B2 |
10016267 | Belson | Jul 2018 | B2 |
10166094 | Russell et al. | Jan 2019 | B2 |
10617509 | Kleshinski et al. | Apr 2020 | B2 |
10617510 | Russell | Apr 2020 | B2 |
20010044632 | Daniel et al. | Nov 2001 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020058964 | Addis | May 2002 | A1 |
20020111648 | Kusleika | Aug 2002 | A1 |
20020128680 | Pavlovic | Sep 2002 | A1 |
20030040736 | Stevens et al. | Feb 2003 | A1 |
20030100940 | Yodfat | May 2003 | A1 |
20030171803 | Shimon | Sep 2003 | A1 |
20040034380 | Woolfson et al. | Feb 2004 | A1 |
20040073253 | Morrill et al. | Apr 2004 | A1 |
20040138692 | Phung et al. | Jul 2004 | A1 |
20040215167 | Belson | Oct 2004 | A1 |
20040225354 | Allen et al. | Nov 2004 | A1 |
20050010246 | Streeter et al. | Jan 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20060173490 | Lafontaine | Aug 2006 | A1 |
20060287668 | Fawzi et al. | Dec 2006 | A1 |
20060293706 | Shimon | Dec 2006 | A1 |
20070027534 | Bergheim et al. | Feb 2007 | A1 |
20070060944 | Boldenow et al. | Mar 2007 | A1 |
20070073246 | Simon | Mar 2007 | A1 |
20070073332 | Miller et al. | Mar 2007 | A1 |
20080027481 | Gilson et al. | Jan 2008 | A1 |
20090149881 | Vale et al. | Jun 2009 | A1 |
20100010535 | Mujkanovic | Jan 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100274277 | Eaton | Oct 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20100305604 | Pah | Dec 2010 | A1 |
20100312268 | Belson | Dec 2010 | A1 |
20120016408 | Barbut et al. | Jan 2012 | A1 |
20120109182 | Belson | May 2012 | A1 |
20120172915 | Fifer | Jul 2012 | A1 |
20120271340 | Castellano et al. | Oct 2012 | A1 |
20130035716 | Belson | Feb 2013 | A1 |
20130035717 | Belson | Feb 2013 | A1 |
20130096606 | Bruchman et al. | Apr 2013 | A1 |
20130178891 | Russell | Jul 2013 | A1 |
20130245669 | Basu et al. | Sep 2013 | A1 |
20130267993 | Carpenter | Oct 2013 | A1 |
20140000091 | Angel et al. | Jan 2014 | A1 |
20140058372 | Belson | Feb 2014 | A1 |
20140214069 | Franklin | Jul 2014 | A1 |
20140249568 | Adams et al. | Sep 2014 | A1 |
20140277096 | Richter | Sep 2014 | A1 |
20150066075 | Russell et al. | Mar 2015 | A1 |
20150320540 | Belson | Nov 2015 | A1 |
20150342717 | O'Donnell | Dec 2015 | A1 |
20150366650 | Zl et al. | Dec 2015 | A1 |
20160296315 | Yachia | Oct 2016 | A1 |
20160317277 | Carpenter et al. | Nov 2016 | A1 |
20170181835 | Kleshinski et al. | Jun 2017 | A1 |
20180042390 | Russell et al. | Feb 2018 | A1 |
20180206970 | Eggert et al. | Jul 2018 | A1 |
20190015152 | Howard et al. | Jan 2019 | A1 |
20200054432 | Martin | Feb 2020 | A1 |
Number | Date | Country |
---|---|---|
2609800 | Jan 2007 | CA |
101351242 | Jan 2009 | CN |
102256566 | Nov 2011 | CN |
102973332 | Mar 2013 | CN |
H09276414 | Oct 1997 | JP |
2007527264 | Sep 2007 | JP |
WO-03094791 | Nov 2003 | WO |
WO-2004019817 | Mar 2004 | WO |
WO-2004021922 | Mar 2004 | WO |
WO-2006138391 | Dec 2006 | WO |
WO-2009038799 | Mar 2009 | WO |
WO-2013103979 | Jul 2013 | WO |
WO-2016040923 | Mar 2016 | WO |
WO-2016040923 | Aug 2016 | WO |
WO-2017116828 | Jul 2017 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn) |
International Search Report and Written Opinion for PCT/US2020/018128 dated May 11, 2020. |
Number | Date | Country | |
---|---|---|---|
20200253709 A1 | Aug 2020 | US |
Number | Date | Country | |
---|---|---|---|
62844941 | May 2019 | US | |
62804909 | Feb 2019 | US |